LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat reports.

That people-first mentality is also reflected in Mazda’s focus on employee wellness – mental, physical, and financial. The ...

BURLINGTON, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- (Nasdaq:LMAT) announced today that it is participating in two upcoming ...

At close: November 22 at 4:00 PM EST ...

LeMaitre Vascular Inc. (LMAT)股价已达到令人印象深刻的里程碑，飙升至106.78美元的历史新高。这一峰值反映了投资者信心的显著增强，从公司近一年97.17%的惊人涨幅中可见一斑，股价几乎翻倍。这家以创新血管外科产品闻名的医疗设备公司正经历一段强劲增长期，吸引了行业分析师和投资者的关注。这一历史新高为LeMaitre ...

LeMaitre continues to expand in the peripheral vascular disease market, with recent revenue gains driven by premium pricing and international growth. Its strong dividend growth of 14.3% this year ...

Mutual of America Capital Management LLC lessened its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) by 1.5% ...

LeMaitre Vascular Inc. (NASDAQ:LMAT)的董事Lawrence J. Jasinski最近出售了198股公司普通股。这笔交易发生于2024年11月20日，每股成交价为103.50美元，总价值约为20,493美元。此次出售后，Jasinski仍持有公司5,111股股份。这项交易已在提交给美国证券交易委员会的监管文件中披露。

A large exercise of company stock options by George LeMaitre, Chairman and CEO at LeMaitre Vascular (NASDAQ:LMAT) was disclosed in a new SEC filing on November 26, as part of an insider exercise.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor ...